;PMID: 11075851
;source_file_673.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..41] = [t:0..41]
;1)sentence:[e:46..118] = [t:46..118]
;2)section:[e:122..233] = [t:122..233]
;3)section:[e:237..330] = [t:237..330]
;4)sentence:[e:334..430] = [t:334..430]
;5)sentence:[e:431..523] = [t:431..523]
;6)sentence:[e:524..607] = [t:524..607]
;7)sentence:[e:608..741] = [t:608..741]
;8)sentence:[e:742..806] = [t:742..806]
;9)sentence:[e:808..921] = [t:808..921]
;10)sentence:[e:922..961] = [t:922..961]
;11)sentence:[e:963..1131] = [t:963..1131]
;12)sentence:[e:1132..1209] = [t:1132..1209]
;13)sentence:[e:1210..1326] = [t:1210..1326]
;14)sentence:[e:1327..1461] = [t:1327..1461]
;15)sentence:[e:1462..1689] = [t:1462..1689]
;16)sentence:[e:1690..1816] = [t:1690..1816]
;17)sentence:[e:1818..1950] = [t:1818..1950]
;18)sentence:[e:1951..2068] = [t:1951..2068]
;19)sentence:[e:2069..2118] = [t:2069..2118]
;20)sentence:[e:2119..2353] = [t:2119..2353]
;21)sentence:[e:2354..2504] = [t:2354..2504]
;22)section:[e:2508..2553] = [t:2508..2553]

;section 0 Span:0..41
;Am J Surg Pathol  2000 Nov;24(11):1501-10
(SEC
  (FRAG (NNP:[0..2] Am) (NNP:[3..4] J) (NNP:[5..9] Surg) (NNP:[10..16] Pathol)
        (CD:[18..22] 2000) (.:[23..30] Nov;24-LRB-) (CD:[30..32] 11)
        (-RRB-:[32..33] -RRB-) (CD:[33..38] :1501) (::[38..39] -)
        (CD:[39..41] 10)))

;sentence 1 Span:46..118
;Carcinoid tumors of the extrahepatic bile ducts: a study of seven cases.
;[46..93]:malignancy:"Carcinoid tumors of the extrahepatic bile ducts"
(SENT
  (NP-HLN
    (NP
      (NP (JJ:[46..55] Carcinoid) (NNS:[56..62] tumors))
      (PP (IN:[63..65] of)
        (NP (DT:[66..69] the) (JJ:[70..82] extrahepatic) (NN:[83..87] bile)
            (NNS:[88..93] ducts))))
    (::[93..94] :)
    (NP
      (NP (DT:[95..96] a) (NN:[97..102] study))
      (PP (IN:[103..105] of)
        (NP (CD:[106..111] seven) (NNS:[112..117] cases))))
    (.:[117..118] .)))

;section 2 Span:122..233
;Maitra A, Krueger JE, Tascilar M, Offerhaus GJ, Angeles-Angeles A, Klimstra
;DS,  Hruban RH, Albores-Saavedra J.
(SEC
  (FRAG (NNP:[122..128] Maitra) (NNP:[129..130] A) (,:[130..131] ,)
        (NNP:[132..139] Krueger) (NNP:[140..142] JE) (,:[142..143] ,)
        (NNP:[144..152] Tascilar) (NNP:[153..155] M,) (NNP:[156..165] Offerhaus)
        (NNP:[166..168] GJ) (NNP:[168..169] ,) (NNP:[170..177] Angeles)
        (::[177..178] -) (NNP:[178..185] Angeles) (NNP:[186..187] A)
        (,:[187..188] ,) (NNP:[189..197] Klimstra) (NNP:[198..200] DS)
        (,:[200..201] ,) (NNP:[203..209] Hruban) (NNP:[210..212] RH)
        (,:[212..213] ,) (NNP:[214..221] Albores) (::[221..222] -)
        (NNP:[222..230] Saavedra) (NNP:[231..233] J.)))

;section 3 Span:237..330
;Department of Pathology, University of Texas Southwestern Medical Center,
;Dallas  75235, USA.
(SEC
  (FRAG (NNP:[237..247] Department) (IN:[248..250] of)
        (NNP:[251..260] Pathology) (,:[260..261] ,) (NNP:[262..272] University)
        (IN:[273..275] of) (NNP:[276..281] Texas) (NNP:[282..294] Southwestern)
        (NNP:[295..302] Medical) (NNP:[303..309] Center) (,:[309..310] ,)
        (NNP:[311..317] Dallas) (VBD:[319..324] 75235) (NNP:[324..325] ,)
        (NNP:[326..329] USA) (.:[329..330] .)))

;sentence 4 Span:334..430
;The authors report seven patients with carcinoid tumors of the extrahepatic
;bile  ducts (EHBDs).
;[373..421]:malignancy:"carcinoid tumors of the extrahepatic bile  ducts"
;[423..428]:malignancy:"EHBDs"
(SENT
  (S
    (NP-SBJ (DT:[334..337] The) (NNS:[338..345] authors))
    (VP (VBP:[346..352] report)
      (NP
        (NP (CD:[353..358] seven) (NNS:[359..367] patients))
        (PP (IN:[368..372] with)
          (NP
            (NP (JJ:[373..382] carcinoid) (NNS:[383..389] tumors))
            (PP (IN:[390..392] of)
              (NP
                (NP (DT:[393..396] the) (JJ:[397..409] extrahepatic)
                    (NN:[410..414] bile) (NNS:[416..421] ducts))
                (NP (-LRB-:[422..423] -LRB-) (NNS:[423..428] EHBDs)
                    (-RRB-:[428..429] -RRB-))))))))
    (.:[429..430] .)))

;sentence 5 Span:431..523
;All patients were women, with an average age at diagnosis of 49.8  years
;(range, 37-67 yrs).
(SENT
  (S
    (NP-SBJ (DT:[431..434] All) (NNS:[435..443] patients))
    (VP (VBD:[444..448] were)
      (NP-PRD
        (NP (NNS:[449..454] women))
        (,:[454..455] ,)
        (PP (IN:[456..460] with)
          (NP
            (NP (DT:[461..463] an) (JJ:[464..471] average) (NN:[472..475] age))
            (PP-TMP (IN:[476..478] at)
              (NP (NN:[479..488] diagnosis)))
            (PP (IN:[489..491] of)
              (NP (CD:[492..496] 49.8) (NNS:[498..503] years)
                (PRN (-LRB-:[504..505] -LRB-)
                  (S
                    (NP-SBJ (NN:[505..510] range))
                    (,:[510..511] ,)
                    (NP-PRD
                      (QP (CD:[512..514] 37) (HYPH:[514..515] -)
                          (CD:[515..517] 67))
                      (NNS:[518..521] yrs)))
                  (-RRB-:[521..522] -RRB-))))))))
    (.:[522..523] .)))

;sentence 6 Span:524..607
;The most common presenting symptom was painless  jaundice with or without
;pruritus.
(SENT
  (S
    (NP-SBJ (DT:[524..527] The)
      (ADJP (RBS:[528..532] most) (JJ:[533..539] common))
      (VBG:[540..550] presenting) (NN:[551..558] symptom))
    (VP (VBD:[559..562] was)
      (NP-PRD
        (NP (JJ:[563..571] painless) (NN:[573..581] jaundice))
        (PP (IN:[582..586] with) (CC:[587..589] or) (IN:[590..597] without)
          (NP (NN:[598..606] pruritus)))))
    (.:[606..607] .)))

;sentence 7 Span:608..741
;Although one patient had peptic ulcer disease  before the onset of
;obstructive jaundice, none had systemic endocrine  manifestations.
(SENT
  (S
    (SBAR-ADV (IN:[608..616] Although)
      (S
        (NP-SBJ (CD:[617..620] one) (NN:[621..628] patient))
        (VP (VBD:[629..632] had)
          (NP (JJ:[633..639] peptic) (NN:[640..645] ulcer)
              (NN:[646..653] disease))
          (PP-TMP (IN:[655..661] before)
            (NP
              (NP (DT:[662..665] the) (NN:[666..671] onset))
              (PP (IN:[672..674] of)
                (NP (JJ:[675..686] obstructive) (NN:[687..695] jaundice))))))))
    (,:[695..696] ,)
    (NP-SBJ (NN:[697..701] none))
    (VP (VBD:[702..705] had)
      (NP (JJ:[706..714] systemic) (JJ:[715..724] endocrine)
          (NNS:[726..740] manifestations)))
    (.:[740..741] .)))

;sentence 8 Span:742..806
;These neoplasms were most often located in the common bile duct.
;[748..757]:malignancy:"neoplasms"
(SENT
  (S
    (NP-SBJ-1 (DT:[742..747] These) (NNS:[748..757] neoplasms))
    (VP (VBD:[758..762] were)
      (ADVP-TMP (RBS:[763..767] most) (RB:[768..773] often))
      (VP (VBN:[774..781] located)
        (NP-1 (-NONE-:[781..781] *))
        (PP-LOC (IN:[782..784] in)
          (NP (DT:[785..788] the) (JJ:[789..795] common) (NN:[796..800] bile)
              (NN:[801..805] duct)))))
    (.:[805..806] .)))

;sentence 9 Span:808..921
;Grossly, the carcinoid tumors were usually nodular and poorly demarcated, and
; ranged from 1.1 to 2.7 cm in size.
;[821..837]:malignancy:"carcinoid tumors"
(SENT
  (S
    (ADVP (RB:[808..815] Grossly))
    (,:[815..816] ,)
    (NP-SBJ (DT:[817..820] the)
       (JJ:[821..830] carcinoid) (NNS:[831..837] tumors))
    (VP
      (VP (VBD:[838..842] were)
        (ADVP-TMP (RB:[843..850] usually))
        (ADJP-PRD
          (ADJP (JJ:[851..858] nodular))
          (CC:[859..862] and)
          (ADJP (RB:[863..869] poorly) (VBN:[870..880] demarcated))))
      (,:[880..881] ,) (CC:[882..885] and)
      (VP (VBD:[887..893] ranged)
        (PP
          (PP (IN:[894..898] from)
            (NP
              (NP (CD:[899..902] 1.1)
                (NML-1 (-NONE-:[902..902] *RNR*)))
              (PP-2 (-NONE-:[902..902] *RNR*))))
          (PP (TO:[903..905] to)
            (NP
              (NP (CD:[906..909] 2.7)
                (NML-1 (-NONE-:[909..909] *RNR*)))
              (PP-2 (-NONE-:[909..909] *RNR*))))
          (NML-1 (NN:[910..912] cm))
          (PP-2 (IN:[913..915] in)
            (NP (NN:[916..920] size))))))
    (.:[920..921] .)))

;sentence 10 Span:922..961
;Only one of the neoplasms was polypoid.
;[938..947]:malignancy:"neoplasms"
(SENT
  (S
    (NP-SBJ
      (NP (RB:[922..926] Only) (CD:[927..930] one))
      (PP (IN:[931..933] of)
        (NP (DT:[934..937] the) (NNS:[938..947] neoplasms))))
    (VP (VBD:[948..951] was)
      (ADJP-PRD (JJ:[952..960] polypoid)))
    (.:[960..961] .)))

;sentence 11 Span:963..1131
;Microscopically, the tumors had a trabecular or nesting pattern with
;occasional  tubule formation, and were composed of relatively small cells
;with granular  chromatin.
;[984..990]:malignancy:"tumors"
(SENT
  (S
    (ADVP (RB:[963..978] Microscopically))
    (,:[978..979] ,)
    (NP-SBJ-2 (DT:[980..983] the) (NNS:[984..990] tumors))
    (VP
      (VP (VBD:[991..994] had)
        (NP
          (NP (DT:[995..996] a)
            (NML
              (NML (JJ:[997..1007] trabecular)
                (NML-1 (-NONE-:[1007..1007] *P*)))
              (CC:[1008..1010] or)
              (NML (VBG:[1011..1018] nesting)
                (NML-1 (NN:[1019..1026] pattern)))))
          (PP (IN:[1027..1031] with)
            (NP (JJ:[1032..1042] occasional) (NN:[1044..1050] tubule)
                (NN:[1051..1060] formation)))))
      (,:[1060..1061] ,) (CC:[1062..1065] and)
      (VP (VBD:[1066..1070] were)
        (VP (VBN:[1071..1079] composed)
          (NP-2 (-NONE-:[1079..1079] *))
          (PP-CLR (IN:[1080..1082] of)
            (NP
              (NP
                (ADJP (RB:[1083..1093] relatively) (JJ:[1094..1099] small))
                (NNS:[1100..1105] cells))
              (PP (IN:[1106..1110] with)
                (NP (JJ:[1111..1119] granular) (NN:[1121..1130] chromatin))))))))
    (.:[1130..1131] .)))

;sentence 12 Span:1132..1209
;All of the neoplasms expressed chromogranin and two expressed 
;synaptophysin.
;[1143..1152]:malignancy:"neoplasms"
;[1163..1175]:gene-protein:"chromogranin"
;[1195..1208]:gene-protein:"synaptophysin"
(SENT
  (S
    (S
      (NP-SBJ
        (NP (DT:[1132..1135] All))
        (PP (IN:[1136..1138] of)
          (NP (DT:[1139..1142] the) (NNS:[1143..1152] neoplasms))))
      (VP (VBD:[1153..1162] expressed)
        (NP (NN:[1163..1175] chromogranin))))
    (CC:[1176..1179] and)
    (S
      (NP-SBJ (CD:[1180..1183] two))
      (VP (VBD:[1184..1193] expressed)
        (NP (NN:[1195..1208] synaptophysin))))
    (.:[1208..1209] .)))

;sentence 13 Span:1210..1326
;Three expressed serotonin and two of the three were also  immunoreactive for
;pancreatic polypeptide or somatostatin.
;[1287..1309]:gene-protein:"pancreatic polypeptide"
;[1313..1325]:gene-protein:"somatostatin"
(SENT
  (S
    (S
      (NP-SBJ (CD:[1210..1215] Three))
      (VP (VBD:[1216..1225] expressed)
        (NP (NN:[1226..1235] serotonin))))
    (CC:[1236..1239] and)
    (S
      (NP-SBJ
        (NP (CD:[1240..1243] two))
        (PP (IN:[1244..1246] of)
          (NP (DT:[1247..1250] the) (CD:[1251..1256] three))))
      (VP (VBD:[1257..1261] were)
        (ADVP (RB:[1262..1266] also))
        (ADJP-PRD (JJ:[1268..1282] immunoreactive)
          (PP (IN:[1283..1286] for)
            (NP
              (NP
                (ADJP-1 (JJ:[1287..1297] pancreatic))
                (NN:[1298..1309] polypeptide))
              (CC:[1310..1312] or)
              (NP
                (ADJP-1 (-NONE-:[1312..1312] *P*))
                (NN:[1313..1325] somatostatin)))))))
    (.:[1325..1326] .)))

;sentence 14 Span:1327..1461
;Two tumors were  focally positive for gastrin and one of these two tumors was
;also positive for  serotonin and pancreatic polypeptide.
;[1331..1337]:malignancy:"tumors"
;[1365..1372]:gene-protein:"gastrin"
;[1394..1400]:malignancy:"tumors"
;[1438..1460]:gene-protein:"pancreatic polypeptide"
(SENT
  (S
    (S
      (NP-SBJ (CD:[1327..1330] Two) (NNS:[1331..1337] tumors))
      (VP (VBD:[1338..1342] were)
        (ADVP (RB:[1344..1351] focally))
        (ADJP-PRD (JJ:[1352..1360] positive)
          (PP (IN:[1361..1364] for)
            (NP (NN:[1365..1372] gastrin))))))
    (CC:[1373..1376] and)
    (S
      (NP-SBJ
        (NP (CD:[1377..1380] one))
        (PP (IN:[1381..1383] of)
          (NP (DT:[1384..1389] these) (CD:[1390..1393] two)
              (NNS:[1394..1400] tumors))))
      (VP (VBD:[1401..1404] was)
        (ADVP (RB:[1405..1409] also))
        (ADJP-PRD (JJ:[1410..1418] positive)
          (PP (IN:[1419..1422] for)
            (NP
              (NP (NN:[1424..1433] serotonin))
              (CC:[1434..1437] and)
              (NP (JJ:[1438..1448] pancreatic) (NN:[1449..1460] polypeptide)))))))
    (.:[1460..1461] .)))

;sentence 15 Span:1462..1689
;All seven carcinoid tumors showed no  immunoreactivity for p53, and assays
;for p53 loss of heterozygosity analysis  were negative in two, suggesting
;that p53 mutations do not play a role in the  pathogenesis of EHBD
;carcinoids.
;[1472..1488]:malignancy:"carcinoid tumors"
;[1521..1524]:gene-protein:"p53"
;[1541..1544]:gene-rna:"p53"
;[1545..1567]:variation-type:"loss of heterozygosity"
;[1616..1619]:gene-rna:"p53"
;[1673..1688]:malignancy:"EHBD carcinoids"
(SENT
  (S
    (S
      (NP-SBJ (DT:[1462..1465] All) (CD:[1466..1471] seven)
         (JJ:[1472..1481] carcinoid) (NNS:[1482..1488] tumors))
      (VP (VBD:[1489..1495] showed)
        (NP
          (NP (DT:[1496..1498] no) (NN:[1500..1516] immunoreactivity))
          (PP (IN:[1517..1520] for)
            (NP (NN:[1521..1524] p53))))))
    (,:[1524..1525] ,) (CC:[1526..1529] and)
    (S
      (NP-SBJ
        (NP (NNS:[1530..1536] assays))
        (PP (IN:[1537..1540] for)
          (NP
            (NML (NN:[1541..1544] p53)
              (NML
                (NML (NN:[1545..1549] loss))
                (PP (IN:[1550..1552] of)
                  (NP (NN:[1553..1567] heterozygosity)))))
            (NN:[1568..1576] analysis))))
      (VP (VBD:[1578..1582] were)
        (ADJP-PRD (JJ:[1583..1591] negative))
        (PP-LOC (IN:[1592..1594] in)
          (NP (CD:[1595..1598] two)))
        (,:[1598..1599] ,)
        (S-ADV
          (NP-SBJ (-NONE-:[1599..1599] *))
          (VP (VBG:[1600..1610] suggesting)
            (SBAR (IN:[1611..1615] that)
              (S
                (NP-SBJ (NN:[1616..1619] p53) (NNS:[1620..1629] mutations))
                (VP (VBP:[1630..1632] do) (RB:[1633..1636] not)
                  (VP (VB:[1637..1641] play)
                    (NP (DT:[1642..1643] a) (NN:[1644..1648] role))
                    (PP (IN:[1649..1651] in)
                      (NP
                        (NP (DT:[1652..1655] the) (NN:[1657..1669] pathogenesis))
                        (PP (IN:[1670..1672] of)
                          (NP (NN:[1673..1677] EHBD)
                              (NNS:[1678..1688] carcinoids)))))))))))))
    (.:[1688..1689] .)))

;sentence 16 Span:1690..1816
;A mutation in codon 12 of K-ras was found in  one carcinoid tumor whereas two
;of two showed immunoreactivity for Dpc4 protein.
;[1692..1700]:variation-event:"mutation"
;[1704..1712]:variation-location:"codon 12"
;[1716..1721]:gene-rna:"K-ras"
;[1740..1755]:malignancy:"carcinoid tumor"
;[1803..1807]:gene-protein:"Dpc4"
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[1690..1691] A) (NN:[1692..1700] mutation))
      (PP-LOC (IN:[1701..1703] in)
        (NP
          (NP (NN:[1704..1709] codon) (CD:[1710..1712] 12))
          (PP (IN:[1713..1715] of)
            (NP (NN:[1716..1721] K-ras))))))
    (VP (VBD:[1722..1725] was)
      (VP (VBN:[1726..1731] found)
        (NP-1 (-NONE-:[1731..1731] *))
        (PP-LOC (IN:[1732..1734] in)
          (NP (CD:[1736..1739] one)
             (JJ:[1740..1749] carcinoid) (NN:[1750..1755] tumor)))
        (SBAR-ADV (IN:[1756..1763] whereas)
          (S
            (NP-SBJ
              (NP (CD:[1764..1767] two))
              (PP (IN:[1768..1770] of)
                (NP (CD:[1771..1774] two))))
            (VP (VBD:[1775..1781] showed)
              (NP
                (NP (NN:[1782..1798] immunoreactivity))
                (PP (IN:[1799..1802] for)
                  (NP (NN:[1803..1807] Dpc4) (NN:[1808..1815] protein)))))))))
    (.:[1815..1816] .)))

;sentence 17 Span:1818..1950
;In view of the small number of carcinoids studied, the importance of these 
;findings in the pathogenesis of these tumors is unclear.
;[1849..1859]:malignancy:"carcinoids"
;[1932..1938]:malignancy:"tumors"
(SENT
  (S
    (PP (IN:[1818..1820] In)
      (NP
        (NP (NN:[1821..1825] view))
        (PP (IN:[1826..1828] of)
          (NP
            (NP (DT:[1829..1832] the) (JJ:[1833..1838] small)
                (NN:[1839..1845] number))
            (PP (IN:[1846..1848] of)
              (NP
                (NP (NNS:[1849..1859] carcinoids))
                (VP (VBN:[1860..1867] studied)
                  (NP (-NONE-:[1867..1867] *)))))))))
    (,:[1867..1868] ,)
    (NP-SBJ
      (NP (DT:[1869..1872] the) (NN:[1873..1883] importance))
      (PP (IN:[1884..1886] of)
        (NP (DT:[1887..1892] these) (NNS:[1894..1902] findings)))
      (PP (IN:[1903..1905] in)
        (NP
          (NP (DT:[1906..1909] the) (NN:[1910..1922] pathogenesis))
          (PP (IN:[1923..1925] of)
            (NP (DT:[1926..1931] these) (NNS:[1932..1938] tumors))))))
    (VP (VBZ:[1939..1941] is)
      (ADJP-PRD (JJ:[1942..1949] unclear)))
    (.:[1949..1950] .)))

;sentence 18 Span:1951..2068
;Ultrastructural  examination of three of the tumors revealed numerous
;membrane-bound, round  neurosecretory granules.
;[1996..2002]:malignancy:"tumors"
(SENT
  (S
    (NP-SBJ
      (NP (JJ:[1951..1966] Ultrastructural) (NN:[1968..1979] examination))
      (PP (IN:[1980..1982] of)
        (NP
          (NP (CD:[1983..1988] three))
          (PP (IN:[1989..1991] of)
            (NP (DT:[1992..1995] the) (NNS:[1996..2002] tumors))))))
    (VP (VBD:[2003..2011] revealed)
      (NP (JJ:[2012..2020] numerous)
        (ADJP (NN:[2021..2029] membrane) (HYPH:[2029..2030] -)
              (VBN:[2030..2035] bound))
        (,:[2035..2036] ,) (JJ:[2037..2042] round)
         (JJ:[2044..2058] neurosecretory) (NNS:[2059..2067] granules)))
    (.:[2067..2068] .)))

;sentence 19 Span:2069..2118
;Clinically, these lesions had an indolent course.
;[2087..2094]:malignancy:"lesions"
(SENT
  (S
    (ADVP (RB:[2069..2079] Clinically))
    (,:[2079..2080] ,)
    (NP-SBJ (DT:[2081..2086] these) (NNS:[2087..2094] lesions))
    (VP (VBD:[2095..2098] had)
      (NP (DT:[2099..2101] an) (JJ:[2102..2110] indolent)
          (NN:[2111..2117] course)))
    (.:[2117..2118] .)))

;sentence 20 Span:2119..2353
;Even  in the presence of lymph node metastases (noted in two patients), all
;of the  patients remained disease free 2 to 11 years (average follow up, 6.6
;yrs) after  segmental resection or pancreaticoduodenectomy (Whipple's
;procedure).
;[2144..2165]:malignancy:"lymph node metastases"
(SENT
  (S
    (PP (RB:[2119..2123] Even) (IN:[2125..2127] in)
      (NP
        (NP (DT:[2128..2131] the) (NN:[2132..2140] presence))
        (PP (IN:[2141..2143] of)
          (NP
            
            (NML (NN:[2144..2149] lymph) (NN:[2150..2154] node))
            (NNS:[2155..2165] metastases)
            (PRN (-LRB-:[2166..2167] -LRB-)
              (VP (VBN:[2167..2172] noted)
                (NP (-NONE-:[2172..2172] *))
                (PP (IN:[2173..2175] in)
                  (NP (CD:[2176..2179] two) (NNS:[2180..2188] patients))))
              (-RRB-:[2188..2189] -RRB-))))))
    (,:[2189..2190] ,)
    (NP-SBJ
      (NP (DT:[2191..2194] all))
      (PP (IN:[2195..2197] of)
        (NP (DT:[2198..2201] the) (NNS:[2203..2211] patients))))
    (VP (VBD:[2212..2220] remained)
      (ADJP-PRD (NN:[2221..2228] disease) (JJ:[2229..2233] free))
      (NP-TMP
        (NP
          (QP (CD:[2234..2235] 2) (TO:[2236..2238] to) (CD:[2239..2241] 11))
          (NNS:[2242..2247] years))
        (PRN (-LRB-:[2248..2249] -LRB-)
          (NP
            (NP (JJ:[2249..2256] average) (VB:[2257..2263] follow)
                (RP:[2264..2266] up))
            (,:[2266..2267] ,)
            (NP (CD:[2268..2271] 6.6) (NNS:[2272..2275] yrs)))
          (-RRB-:[2275..2276] -RRB-))
        (PP-TMP (IN:[2277..2282] after)
          (NP
            (NP (JJ:[2284..2293] segmental) (NN:[2294..2303] resection))
            (CC:[2304..2306] or)
            (NP (NN:[2307..2330] pancreaticoduodenectomy)
              (PRN (-LRB-:[2331..2332] -LRB-)
                (NP
                  (NP (NNP:[2332..2339] Whipple) (POS:[2339..2341] 's))
                  (NN:[2342..2351] procedure))
                (-RRB-:[2351..2352] -RRB-)))))))
    (.:[2352..2353] .)))

;sentence 21 Span:2354..2504
;Because  carcinoid tumors of the EHBD are of low malignant potential, they
;should be  separated from the more common adenocarcinomas in this location.
;[2363..2391]:malignancy:"carcinoid tumors of the EHBD"
;[2471..2486]:malignancy:"adenocarcinomas"
(SENT
  (S
    (SBAR-PRP (IN:[2354..2361] Because)
      (S
        (NP-SBJ
          (NP (JJ:[2363..2372] carcinoid) (NNS:[2373..2379] tumors))
          (PP (IN:[2380..2382] of)
            (NP (DT:[2383..2386] the) (NN:[2387..2391] EHBD))))
        (VP (VBP:[2392..2395] are)
          (PP-PRD (IN:[2396..2398] of)
            (NP (JJ:[2399..2402] low) (JJ:[2403..2412] malignant)
                (NN:[2413..2422] potential))))))
    (,:[2422..2423] ,)
    (NP-SBJ-1 (PRP:[2424..2428] they))
    (VP (MD:[2429..2435] should)
      (VP (VB:[2436..2438] be)
        (VP (VBN:[2440..2449] separated)
          (NP-1 (-NONE-:[2449..2449] *))
          (PP-CLR (IN:[2450..2454] from)
            (NP
              (NP (DT:[2455..2458] the)
                (ADJP (RBR:[2459..2463] more) (JJ:[2464..2470] common))
                (NNS:[2471..2486] adenocarcinomas))
              (PP (IN:[2487..2489] in)
                (NP (DT:[2490..2494] this) (NN:[2495..2503] location))))))))
    (.:[2503..2504] .)))

;section 22 Span:2508..2553
;PMID: 11075851 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[2508..2512] PMID) (::[2512..2513] :) (CD:[2514..2522] 11075851)
        (NN:[2523..2524] -LSB-) (NNP:[2524..2530] PubMed) (::[2531..2532] -)
        (NN:[2533..2540] indexed) (IN:[2541..2544] for)
        (NNP:[2545..2553] MEDLINE-RSB-)))
